The HIV-1 envelope glycoprotein transmembrane subunit, gp41, mediates the fusion of viral and target cell membranes. The 2 helical regions in the ectodomain of gp41, the N-helix and the C-helix, form a helical bundle complex that has been suggested as a fusion-active conformation. Previously, an enzyme-linked immunosorbent assay (ELISA) method had been established to measure the interaction of 2 helical regions of gp41. In this study, the ELISA method was modified to apply high-throughput screening (HTS) of an organic compound library. A few compounds had been identified to prevent the interaction between 2 helical regions of gp41, and they were further shown to inhibit the gp41-mediated viral infection. In addition, they specifically quenched the fluorescence of tryptophan in the N-helix region, indicating that these compounds bound to the N-helix rather than the C-helix of gp41. These results suggested that this assay method targeting gp41 could be used for HTS of HIV fusion inhibitors. (Journal of Biomolecular Screening 2005:13-19)
Vaishnav YN, Wong-Staal F: The biochemistry of AIDS. Ann Rev Biochem1991;60:577-630.
2.
Berger EA, Murphy PM, Farber JM: Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Ann Rev Immunol1999;17:657-700.
3.
D’Souza MP, Harden VA: Chemokines and HIV-1 second receptors: confluence of two fields generates optimism in AIDS research. Nat Med1996;2:1293-1300.
4.
Wilkinson D: HIV-1: cofactors provide the entry keys. Curr Biol1996;6:1051-1053.
5.
Skehel JJ, Wiley DC: Coiled coils in both intracellular vesicle and viralmembrane fusion. Cell1998;95:871-874.
6.
Gallaher WR: Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus. Cell1987;50:327-328.
7.
Bosch ML, Earl PL, Fargnoli K, et al: Identification of the fusion peptide of primate immunodeficiency viruses. Science1989;244:694-697.
8.
Rabenstein M, Shin YK: A peptide from the heptad repeat of human immunodeficiency virus gp41 shows both membrane binding and coiled-coil formation. Biochemistry1995;34:13390-13397.
9.
Shugars DC, Wild CT, Greenwell TK, Matthews TJ: Biophysical characterization of recombinant proteins expressing the leucine zipper-like domain of the human immunodeficiency virus type 1 transmembrane protein gp41. J Virol1996;70:2982-2991.
10.
Poumbourios P, Wilson KA, Center RJ, Ahmar WL, Kemp B: Human immunodeficiency virus type 1 envelope glycoprotein oligomerization requires the gp41 amphipathic α-helical/leucine zipper-like sequence. J Virol1997;71:2041-2049.
11.
Wild C, Dubay JW, Greenwell T, et al: Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci USA1994;91:12676-12680.
12.
Lawless MK, Barney S, Guthrie KI, Bucy TB, Petteway SR Jr, Merutka G: HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically active peptides from gp41. Biochemistry1996;35:13697-13708.
13.
Ryu JR, Jin BS, Suh MJ, et al: Two interaction modes of the gp41-derived peptides with gp41 and their correlation with antimembrane fusion activity. Biochem Biophys Res Comm1999;265:625-629.
14.
Chan DC, Fass D, Berger JM, Kim PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell1997;89:263-273.
15.
Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC: Atomic structure of the ectodomain from HIV-1 gp41. Nature1997;387:426-430.
16.
Lu M, Blacklow SC, Kim PS: A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol1995;2:1075-1082.
17.
Furuta RA, Wild CT, Weng Y, Weiss CD: Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol1998;5:276-279.
18.
Jin BS, Ryu JR, Ahn K, Yu YG: Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses2000;16:1797-1804.
19.
Kilby JM, Hopkins S, Venetta TM, et al: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med1998;4:1302-1307.
20.
Labrosse B, Pleskoff O, Sol N, Jones C, Henin Y, Alizon M: Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41. JVirol1997;71:8230-8236.
21.
Labrosse B, Treboute C, Alizon M: Sensitivity to a nonpeptidic compound (RPR103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop region. JVirol2000;74:2142-2150.
22.
Debnath AK, Radigan L, Jiang S: Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J Med Chem1999;42:3203-3209.
23.
Ryu JR, Lee J, Choo S, Yoon SH, Woo ER, Yu YG: Development of aninvitro assay system for screening of gp41 inhibitory compounds. Mol Cells1998;8:717-723.
24.
Lee MK, Seo JK, Kim HK, Cho JH, Poo H, Kim KL: A vector system for introducing foreign HIV-1 env genes and pseudotyping of MuLV particles with the recombinant HIV-1 envelope proteins for anti-HIV-1 assay. Antiviral Res2002;53:99-111.
25.
Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK: High-titer packaging cells producing recombinant retroviruses resistant to human serum. JVirol1995;69:7430-7436.
26.
Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods1983;65:55-63.
27.
Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen1999;4:67-73.
